Retatrutide (development code LY3437943, Eli Lilly) is a once-weekly injectable peptide that simultaneously activates three receptors involved in energy homeostasis and glucose metabolism: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This unimolecular triple agonism distinguishes it from earlier incretin-based drugs such as semaglutide (GLP-1R only) and tirzepatide (GIP/GLP-1R dual agonist), and has produced body weight reductions in randomized controlled trials that exceed any previously published pharmacological intervention. As of late 2025, Retatrutide remains an investigational compound undergoing Phase 3 trials and is not approved for therapeutic use in any jurisdiction.
The research interest in Retatrutide centers on understanding the additive or synergistic contributions of glucagon receptor agonism to the already well-characterized incretin pathway. While GLP-1R activation suppresses appetite and slows gastric emptying, and GIPR activation amplifies insulin secretion and modulates adipose tissue, glucagon receptor stimulation increases hepatic glucose output and — critically — raises basal energy expenditure through thermogenic mechanisms. The triple-receptor hypothesis holds that controlled glucagon co-agonism, in the context of simultaneous GLP-1R and GIPR engagement, can augment caloric deficit without inducing hyperglycemia, since the insulinotropic effects counterbalance glucagon's glycemic action.
Biochemical Identity & Structural Properties
| Property | Value |
|---|---|
| Development Code | LY3437943 |
| Common Name | Retatrutide |
| Classification | Unimolecular triple incretin receptor agonist |
| Target Receptors | GIPR (GIP receptor), GLP-1R (GLP-1 receptor), GCGR (Glucagon receptor) |
| Structure | Acylated 39-amino acid peptide; fatty acid chain enables albumin binding for extended half-life |
| Molecular Weight | ~4,600 Da (approximate, acylated form) |
| Administration | Once-weekly subcutaneous injection (clinical trials) |
| Half-life | ~6 days (supports weekly dosing) |
| Developer | Eli Lilly and Company |
| Regulatory Status | Investigational; Phase 3 trials ongoing (as of 2025) |
Triple Receptor Mechanism of Action
Structural studies have confirmed that Retatrutide achieves balanced agonism across all three receptor systems through a single peptide backbone optimized to engage each receptor's orthosteric binding site. A 2024 paper in Cell Discovery characterized the structural basis for this triple agonism using cryo-EM, revealing how a single acylated peptide can adopt conformations that activate GLP-1R, GIPR, and GCGR with meaningful potency at each target. (Nature Cell Discovery, 2024)
GLP-1 Receptor (GLP-1R) Agonism
GLP-1R activation suppresses appetite through hypothalamic signaling, slows gastric emptying to reduce caloric intake velocity, and stimulates glucose-dependent insulin secretion from pancreatic beta cells. GLP-1R agonism is the established mechanism behind drugs like semaglutide and liraglutide; in Retatrutide it forms the foundational appetite-suppression and insulin-secretion axis.
GIP Receptor (GIPR) Agonism
GIPR is expressed broadly in adipose tissue, bone, and the central nervous system in addition to the pancreatic beta cell. GIPR co-agonism appears to enhance the weight loss signal from GLP-1R activation and attenuate gastrointestinal side effects. Tirzepatide (Mounjaro/Zepbound) already validated the clinical utility of dual GIP/GLP-1R agonism; Retatrutide adds glucagon receptor activation on top of this proven base.
Glucagon Receptor (GCGR) Agonism
The glucagon receptor component is the mechanistically novel addition in Retatrutide's profile. Glucagon traditionally raises hepatic glucose output; however, GCGR agonism also activates brown adipose tissue thermogenesis and increases basal metabolic rate. Research models suggest that in the context of simultaneous GLP-1R engagement — which drives glucose-dependent insulin release — the net glycemic effect of glucagon co-agonism can be substantially blunted, allowing the energy expenditure benefits to manifest without causing hyperglycemia. Studies in rodent models showed dose-dependent increases in oxygen consumption and reduced respiratory quotient consistent with enhanced lipid oxidation under triple agonist treatment.
Phase 2 Obesity Trial — NEJM 2023
The pivotal Phase 2 efficacy and safety data for Retatrutide in obesity was published by Jastreboff AM et al. in the New England Journal of Medicine on June 26, 2023 (N Engl J Med 2023; 389:514-526 / PMID: 37366315). This 48-week, randomized, double-blind, placebo-controlled trial enrolled 338 participants with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one weight-related comorbidity) but without type 2 diabetes, conducted across sites in the United States.
Dose Groups & Weight Loss at 48 Weeks
| Dose Group | Mean % Body Weight Change (48 wks) | Estimated Absolute Loss* |
|---|---|---|
| Placebo | −2.1% | ~4 lbs |
| Retatrutide 1 mg | −8.7% | ~18 lbs |
| Retatrutide 4 mg (pooled) | −17.1% | ~36 lbs |
| Retatrutide 8 mg (pooled) | −22.8% | ~48 lbs |
| Retatrutide 12 mg | −24.2% | ~58 lbs |
*Approximate absolute loss estimated from reported mean baseline body weight of ~240 lbs (109 kg) in the 12 mg cohort.
Secondary Endpoints & Cardiometabolic Findings
- Prediabetes reversal: 72% of participants with prediabetes at baseline reverted to normoglycemia in the highest-dose group — a striking cardiometabolic finding given no anti-diabetic intent was a primary endpoint.
- Waist circumference: Statistically significant reductions at all active dose arms, consistent with visceral fat mobilization.
- Blood pressure: Dose-dependent reductions in systolic and diastolic blood pressure observed, likely secondary to weight loss and improved insulin sensitivity.
- Lipid panel: Improvements in triglycerides, non-HDL cholesterol, and total cholesterol observed at higher doses.
- No dose plateau detected: The dose-response curve had not reached a clear plateau at 12 mg by 48 weeks, suggesting further weight loss was possible with longer treatment duration — an observation that informed Phase 3 dose selection.
Phase 2 Type 2 Diabetes Trial — The Lancet 2023
A parallel Phase 2 trial evaluated Retatrutide in participants with type 2 diabetes. Results were published in The Lancet on July 2023 (The Lancet, 2023; 402(10401):529–544 / PMID: 37385280). This was a 36-week, randomized, double-blind trial with placebo and active controls conducted in the USA.
Key Findings in Type 2 Diabetes
- HbA1c reduction: Retatrutide produced statistically significant and clinically meaningful reductions in HbA1c versus placebo at all tested doses, with the largest reductions observed in the 12 mg escalation group.
- Body weight reduction: Dose-dependent, ranging from −3.19% (0.5 mg group) to −16.94% (12 mg escalation group) over 36 weeks — substantial weight loss in a population with T2D, where weight loss with antidiabetic agents is typically more limited.
- Safety in diabetes: No unexpected hypoglycemia signals above background; gastrointestinal events (nausea, vomiting, diarrhea) were the dominant adverse effect profile, consistent with the obesity trial.
- Glucagon co-agonism in T2D: The trial provided human data confirming that glucagon receptor agonism within the triple-agonist context does not produce clinically significant hyperglycemia in T2D patients — a critical mechanistic validation of the dual insulinotropic counterbalance hypothesis.
MASLD / Liver Fat Phase 2a Trial — Nature Medicine 2024
A pre-specified substudy of the Phase 2 obesity trial examined liver fat outcomes in participants who had ≥10% liver fat content at baseline as measured by MRI proton density fat fraction (MRI-PDFF). Results were published in Nature Medicine in 2024 (Nature Medicine, 2024 / PMC11271400). Of the 338 main trial participants, 98 (29.1%) met the liver fat inclusion criterion.
Liver Fat Reduction Results (MRI-PDFF)
| Dose | Mean Relative Liver Fat Change (24 wks) | Achieved Normal Liver Fat <5% (24 wks) | Mean Relative Change (48 wks) | Achieved Normal Liver Fat (48 wks) |
|---|---|---|---|---|
| Placebo | +0.3% | 0% | +4.6% | — |
| 1 mg | −42.9% | 27% | — | — |
| 4 mg | −57.0% | 52% | — | — |
| 8 mg | −81.4% | 79% | −81.7% | 89% |
| 12 mg | −82.4% | 86% | −86.0% | 93% |
At 48 weeks, the 12 mg group achieved a mean relative liver fat reduction of 86%, with 93% of participants reaching normal liver fat levels (<5% by MRI-PDFF). Independent hepatologists described these as the most potent pharmacologically-induced liver fat reductions recorded in a clinical trial to date. Liver fat reductions correlated with improvements in insulin resistance biomarkers, including fasting insulin, fasting C-peptide, and HOMA2-IR, which were reduced by up to 50% or more from baseline in higher dose groups.
Phase 3 TRIUMPH-4 Trial Results — December 2025
Eli Lilly announced positive topline results from the Phase 3 TRIUMPH-4 trial in December 2025, the first Phase 3 readout for the Retatrutide program. TRIUMPH-4 was a 68-week, randomized, double-blind, placebo-controlled study enrolling 445 participants with obesity or overweight plus knee osteoarthritis — a design intended to demonstrate both metabolic and musculoskeletal benefits of sustained weight loss. (Eli Lilly Investor Release, December 2025)
TRIUMPH-4 Primary Outcomes
| Endpoint | Retatrutide 9 mg | Retatrutide 12 mg | Placebo |
|---|---|---|---|
| Mean % body weight change (68 wks) | −26.4% | −28.7% | −2.1% |
| Mean absolute weight loss | ~63 lbs | ~71.2 lbs | ~4 lbs |
| WOMAC pain score reduction | Significant | −75.8% (4.5 pts) | Reference |
| Patients free from knee pain | — | 1 in 8 participants | — |
| Non-HDL cholesterol | Significantly reduced vs placebo | Reference | |
| Systolic blood pressure | Significantly reduced vs placebo | Reference | |
The 28.7% mean body weight reduction in the 12 mg arm over 68 weeks — equivalent to an average of 71.2 lbs lost — represents the largest mean weight reduction reported in any Phase 3 obesity pharmacotherapy trial to date. Seven additional Phase 3 readouts from the TRIUMPH program covering type 2 diabetes, cardiovascular disease, and obstructive sleep apnea are expected throughout 2026.
Safety Profile Across Trials
Across Phase 2 and Phase 3 studies, the safety profile of Retatrutide is consistent with the GLP-1 receptor agonist class. The dominant adverse events are gastrointestinal — nausea, vomiting, and diarrhea — occurring primarily during the dose escalation period and generally rated mild to moderate in severity. In TRIUMPH-4, nausea was reported in 43%, vomiting in 21%, and diarrhea in 33% of participants in the highest dose arm. Discontinuation rates due to adverse events were 12.2% (9 mg) and 18.2% (12 mg) versus 4% with placebo.
- Gastrointestinal events: Nausea, vomiting, diarrhea — most common during dose titration; attenuate with prolonged exposure.
- Hypoglycemia: No excess hypoglycemia signals above background in participants without antidiabetic co-medications.
- Heart rate: Modest increase in resting heart rate observed (consistent with GLP-1R agonism class effect), under ongoing monitoring.
- No new safety signals: No unexpected organ toxicity, immune events, or serious adverse effects beyond those seen with approved GLP-1R agonists reported through Phase 3.
- Lean mass preservation: An area of ongoing study; preliminary Phase 2 data suggest the majority of weight lost with Retatrutide is fat mass, with relative preservation of lean body mass — though formal DEXA-confirmed data from Phase 3 is pending.
Comparative Context: Where Retatrutide Sits in the Research Landscape
| Compound | Receptor Targets | Peak Clinical Weight Loss Reported | Status (2025) |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1R | ~15% (STEP-1, 68 wks) | FDA approved |
| Tirzepatide (Zepbound) | GIP/GLP-1R | ~21% (SURMOUNT-1, 72 wks) | FDA approved |
| Retatrutide | GIP/GLP-1R/GCGR | ~28.7% (TRIUMPH-4, 68 wks) | Phase 3 (investigational) |
Key Published References
Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389, 514–526. doi:10.1056/NEJMoa2301972 — PMID: 37366315
Frías JP, Dahl D, Bhupathiraju SN, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet, 402(10401), 529–544. doi:10.1016/S0140-6736(23)01053-X — PMID: 37385280
Loomba R, Hartman ML, Lawitz EJ, et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. doi:10.1038/s41591-024-03018-2 — PMC11271400
Eli Lilly and Company. (December 2025). Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Investor Press Release
Xu Y, Chen Y, Zhao J, et al. (2024). Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. doi:10.1038/s41421-024-00700-0
ClinicalTrials.gov. TRIUMPH registrational clinical trials for Retatrutide. NCT05931367
